kiniksa
announces
phase
clinical
data
vixarelimab
prurigo
nodularis
presented
european
academy
dermatology
venereology
virtual
congress
hamilton
bermuda
globe
newswire
kiniksa
pharmaceuticals
nasdaq
knsa
kiniksa
biopharmaceutical
company
pipeline
assets
designed
modulate
immunological
pathways
across
spectrum
diseases
today
announced
presentation
data
phase
clinical
trial
vixarelimab
prurigo
nodularis
european
academy
dermatology
venereology
eadv
virtual
congress
kiniksa
previously
reported
positive
results
trial
april
vixarelimab
monoclonal
antibody
targets
oncostatin
receptor
beta
osmrβ
howard
sofen
md
associate
clinical
professor
dermatology
david
geffen
ucla
school
medicine
delivered
virtual
presentation
entitled
vixarelimab
reduced
pruritus
improved
nodules
patients
prurigo
nodularis
phase
randomized
study
presentation
available
science
section
kiniksa
website
phase
trial
met
primary
efficacy
endpoint
statistically
significant
reduction
numeric
rating
scale
baseline
week
vixarelimab
recipients
compared
placebo
recipients
additionally
statistically
significant
percentage
vixarelimab
recipients
achieved
prurigo
global
assessment
score
week
compared
placebo
recipients
majority
vixarelimab
recipients
showed
clinically
meaningful
reduction
week
prurigo
nodularis
debilitating
chronic
inflammatory
skin
condition
characterized
severely
pruritic
skin
nodules
significant
unmet
need
remains
said
howard
sofen
md
david
geffen
ucla
school
medicine
phase
study
vixarelimab
demonstrated
significant
reductions
pruritus
disease
currently
therapies
even
encouraging
seeing
significant
nodule
resolution
week
look
forward
investigation
vixarelimab
subsequent
phase
trial
enrolled
patients
prurigo
nodularis
score
score
score
experiencing
pruritus
mean
score
patients
randomized
receive
loading
dose
vixarelimab
mg
placebo
subcutaneous
sc
followed
vixarelimab
mg
placebo
sc
weekly
primary
efficacy
endpoint
percent
change
versus
baseline
week
using
last
observation
carried
forward
analysis
least
change
baseline
week
vixarelimab
recipients
compared
placebo
recipients
mean
difference
median
change
baseline
week
vixarelimab
recipients
compared
placebo
recipients
vixarelimab
recipients
achieved
score
week
compared
placebo
recipients
vixarelimab
recipients
demonstrated
reduction
week
compared
placebo
recipients
phase
trial
vixarelimab
subjects
adverse
experiences
observed
serious
adverse
events
atopic
dermatitis
flares
kiniksa
expects
initiate
phase
clinical
trial
vixarelimab
prurigo
nodularis
fourth
quarter
kiniksa
kiniksa
biopharmaceutical
company
focused
discovering
acquiring
developing
commercializing
therapeutic
medicines
patients
suffering
debilitating
diseases
significant
unmet
medical
need
kiniksa
product
candidates
rilonacept
mavrilimumab
vixarelimab
based
strong
biologic
rationale
validated
mechanisms
target
underserved
conditions
offer
potential
differentiation
pipeline
assets
designed
modulate
immunological
pathways
across
spectrum
diseases
information
please
visit
vixarelimab
vixarelimab
investigational
monoclonal
antibody
targets
osmrβ
mediates
signaling
oncostatin
osm
two
key
cytokines
implicated
pruritus
inflammation
fibrosis
kiniksa
believes
vixarelimab
monoclonal
antibody
development
targets
pathways
simultaneously
kiniksa
lead
indication
vixarelimab
prurigo
nodularis
chronic
inflammatory
skin
condition
vixarelimab
phase
trial
prurigo
nodularis
phase
trial
randomized
study
designed
investigate
efficacy
safety
tolerability
pharmacokinetics
vixarelimab
reducing
pruritus
subjects
prurigo
nodularis
trial
enrolled
patients
prurigo
nodularis
experiencing
pruritus
screening
visit
mean
weekly
two
consecutive
weeks
immediately
prior
randomization
patients
required
stop
antihistamines
topical
treatments
including
corticosteroids
least
two
weeks
prior
dosing
prurigo
nodularis
treatments
study
drug
allowed
except
rescue
information
refer
identifier
statements
information
contained
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
cases
identify
forward
looking
statements
terms
may
expect
plan
anticipate
could
intend
target
project
contemplate
believe
estimate
predict
potential
continue
negative
terms
similar
expressions
although
statements
contain
identifying
words
statements
contained
press
release
relate
matters
historical
fact
considered
statements
including
without
limitation
statements
regarding
timing
planned
clinical
trials
including
timing
kiniksa
initiate
phase
trial
vixarelimab
prurigo
nodularis
fourth
quarter
potential
impact
differentiation
osmrβ
mechanism
potential
vixarelimab
positively
impact
lives
patients
prurigo
nodularis
potential
clinical
stage
product
candidates
offer
differentiation
statements
based
management
current
expectations
statements
neither
promises
guarantees
involve
known
unknown
risks
uncertainties
important
factors
may
cause
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
including
without
limitation
following
potential
changes
final
broader
set
data
interim
preliminary
data
announce
impact
additional
data
us
companies
potential
inability
replicate
later
clinical
trials
positive
results
phase
clinical
trial
vixarelimab
patients
prurigo
nodularis
potential
undesirable
side
effects
caused
vixarelimab
reliance
third
parties
conduct
clinical
trials
vixarelimab
impact
pandemic
measures
taken
response
pandemic
changes
operating
plan
funding
requirements
existing
new
competition
ability
attract
retain
qualified
personnel
important
factors
discussed
caption
risk
factors
annual
report
form
filed
securities
exchange
commission
sec
august
reports
subsequently
filed
furnished
sec
could
cause
actual
results
differ
materially
indicated
statements
made
press
release
statements
represent
management
estimates
date
press
release
may
elect
update
statements
point
future
disclaim
obligation
even
subsequent
events
cause
views
change
statements
relied
upon
representing
views
date
subsequent
date
press
release
every
second
counts
kiniksa
investor
media
contact
mark
ragosa
mragosa
